April 2025 – Page 3

Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions

1 month ago talkbio0Tagged Autoimmune Diseases, B cell immunomodulator program, biology (field), Flatulence, Nordisk alliance, OCT50, Programs - Publication Format

Autoimmune disease biotech, B cell immunomodulator program, OCT50 program, Novo Nordisk alliance, Winding down operations, Unresolved biology challenges

HHS lifts stop work order on Vaxart’s COVID-19 trial, continues funding for the 10,000-participant study

1 month ago talkbio0Tagged BARDA, Covid Vaccine, COVID19 (disease), Lifting, next-generation, oral pill vaccine, Phase 2b Trial, stop work, Vaccines, Vaxart

Vaxart, COVID-19 vaccine, oral pill vaccine, stop work order lifted, BARDA funding, 10, 000-participant study, Phase 2b trial, next-generation COVID vaccine

Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M

1 month ago talkbio0Tagged Approved, Ataxia, Spinocerebellar, Capital, Investments, non-dilutive, Note (document), secured, United States Food and Drug Administration

Biohaven, Oberland Capital, $600 million investment, troriluzole, spinocerebellar ataxia (SCA), non-dilutive funding, FDA approval, senior secured notes

France pauses chikungunya vaccinations in the elderly after patient death

1 month ago talkbio0Tagged Adverse event, Age, Chikungunya Fever, Disease Outbreaks, Elderly (population group), France, Latex Fixation Tests, older, Reunion Island, Vaccination, Vaccines

Vaccines, Chikungunya Fever, Elderly (population group), Adverse event, France, Latex Fixation Tests, Reunion Island, Disease Outbreaks, Age, older, Vaccination

AACR25: Boehringer touts new durability data for zongertinib in targeted lung cancer

1 month ago talkbio0Tagged AACR25, Boehringer, cellular targeting, durability, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Zongertinib

Malignant neoplasm of lung, AACR25, cellular targeting, Boehringer, Non-Small Cell Lung Carcinoma, Zongertinib, Zongertinib, durability

Pfizer’s Sasanlimab Shows 32% Reduction in Bladder Cancer Risk But Misses Secondary Endpoints in Phase 3 CREST Trial

1 month ago talkbio0Tagged BCG Vaccine, Event-Free Survival, Inhibitor, Invasive, Malignant neoplasm of urinary bladder, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Overall Survival, PDCD1 gene, Phase 3 CREST trial, Sasanlimab, subcutaneous administration

Sasanlimab (PD-1 inhibitor), Bladder cancer risk reduction, Phase 3 CREST trial, BCG combination therapy, Non-muscle invasive bladder cancer (NMIBC), Event-free survival (EFS), Overall survival (OS) endpoint missed, Subcutaneous administration

Regeneron Secures EU Approval for Bispecific Antibody Lynozyfic, Positioning for Competition Against J&J and Pfizer

1 month ago talkbio0Tagged Antibodies, Bispecific, Approved, EU, J&J, Lynozyfic, Multiple Myeloma, Neoplasms, Pfizer, Regeneron

Regeneron, Lynozyfic, Bispecific Antibody, Multiple Myeloma, EU Approval, J&J, Pfizer, Oncology

‘Deviated from the core’: Akeso CEO tries to reset expectations of bispecific’s survival readout amid market tumult

1 month ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Keytruda head-to-head trial, Market, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Reaction, summit

Ivonescimab, PD-1xVEGF bispecific antibody, Overall survival (OS) readout, Keytruda head-to-head trial, HARMONi-2 trial, Non-small cell lung cancer (NSCLC), Market reaction, Summit Therapeutics

Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks

1 month ago talkbio0Tagged disease treatments, Fibromatosis, Aggressive, Gomekli, KGaA, Merck KGaA, Neurofibromatosis 1, Ogsiveo, Pfizer, Pfizer/, pharmaceutical acquisition, SpringWorks

Pharmaceutical acquisition, rare disease treatments, Merck KGaA, SpringWorks Therapeutics, Ogsiveo, Gomekli, desmoid tumors, neurofibromatosis type 1 (NF1), Pfizer spinout